Brief: Cipla Expands U.S. Respiratory Portfolio With Approval Of Nintedanib Capsules (100Mg & 150Mg) For Idiopathic Pulmonary Fibrosis
03/04/2026 04:12
April 2 (Reuters) - Cipla Ltd CIPL.NS: CIPLA EXPANDS U.S. RESPIRATORY PORTFOLIO WITH APPROVAL OF NINTEDANIB CAPSULES (100MG & 150MG) FOR IDIOPATHIC PULMONARY FIBROSIS Source text: ID:nPn6WdvDya Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated